Table 57Pooled relative risks and other adverse event rates—epoetin or darbepoetin versus control

OutcomeTrialsESA NControl NRR (95% CI)I2Incidence ESA (95% CI)Incidence Control (95% CI)
Hypertension16a2,3022,0161.48 (1.07 to 2.06)0%3.8% (2.7 to 5.0)2.1% (1.1 to 3.4)
Thrombocytopenia and/or Hemorrhage122,0181,6961.17 (1.01 to 1.36)0%12.2% (5.5 to 20.9)9.9% (3.9 to 17.8)
Rash5b7397282.00 (0.98 to 4.07)0%2.3% (0.2 to 5.6)1.0% (0.0 to 3.3)
Seizures58547330.93 (0.43 to 2.04)0%2.1% (1.2 to 3.1)1.8% (0.6 to 3.7)

CI = confidence interval; ESA = erythropoiesis-stimulating agent; RR = relative risk

a

Excluding one trial with no events106 and one outlier.118

b

Result excludes one trial with no events.103

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.